Some recent analyst ratings include

• 11/8/2019-
  AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by HC Wainwright with a $9.00 price target
• 8/5/2019-
  AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Outperform ➝ Outperform rating and $7.00 price target
• 5/9/2019-
  AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Buy rating reiterated by LADENBURG THALM/SH SH with a $10.00 price target
• 4/24/2019-
  AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) has coverage initiated with a Buy ➝ Buy rating and $6.50 price target
• 12/11/2018-
  AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) had its Hold rating reiterated by Oppenheimer

• On 8/26/2019 Mark G Edwards, Director, bought 15,000 with an average share price of $2.19 per share and the total transaction amounting to $32,850.00.
• On 8/23/2019 Mark G Edwards, Director, bought 10,000 with an average share price of $2.20 per share and the total transaction amounting to $22,000.00.
• On 6/5/2019 Vincent J Angotti, CEO, bought 5,000 with an average share price of $2.31 per share and the total transaction amounting to $11,550.00.
• On 3/12/2019 Mark G Edwards, Director, bought 19,000 with an average share price of $2.99 per share and the total transaction amounting to $56,810.00.
• On 2/28/2019 Pamela P Palmer, Insider, bought 840 with an average share price of $2.81 per share and the total transaction amounting to $2,360.40.
• On 2/28/2019 Raffi Asadorian, CFO, bought 3,647 with an average share price of $2.81 per share and the total transaction amounting to $10,248.07.
• On 2/28/2019 Vincent J Angotti, CEO, bought 3,234 with an average share price of $2.81 per share and the total transaction amounting to $9,087.54.

Recent Trading Activity for